

TABLE 1.—CLASSIFICATION OF THE 28 PATIENTS AND RESULTS OF INDOMETHACIN TRIAL

Pt. No.	Sex	Age (yr.)	AS onset (yr.)	Indomethacin		Functional class ¹		ESR		Individual improvement ² in			Overall response ³	Side effects and month first noted
				Daily maintenance (mg.)	Length of Rx (mo.)	Before Rx	After Rx	Before Rx	After Rx	Joint pain	AM stiffness	Onset of fatigue	Joint mobility	
(1).....	F	53	25	100	39	III	II	98	18	+	+	—	+	
(2).....	M	39	15	100	20	II	II	35	10	+	+	—	+	
(3).....	M	45	30	175	20	II	II	54	42	+	+	—	+	
(4).....	M	47	24	100	18	II	II	100	71	+	+	—	+	
(5).....	M	27	14	100	39	II	II	98	47	+	+	—	+	
(6).....	M	47	40	100	40	II	II	34	15	+	+	—	+	Nausea, 2d month; dizziness, 2d month.
(7).....	M	46	40	100	51	II	II	5	15	+	+	—	+	
(8).....	M	53	33	125	51	II	II	23	35	+	+	—	+	
(9).....	M	58	31	100	41	II	II	67	7	+	+	—	+	
(10).....	M	51	17	200	51	III	II	61	28	+	+	—	+	Headache, 6th month; nausea, 29th month; diarrhea, 34th month.
(11).....	F	49	14	25	45	II	II	61	28	+	+	—	+	Headache, 24th month.
(12).....	M	23	14	200	27	II	II	3	6	+	+	—	+	Headache, 2d month.
(13).....	M	53	32	100	17	II	II	37	10	+	+	—	+	Dizziness, 2d month.
(14).....	M	48	40	100	18	II	II	37	32	+	+	—	+	
(15).....	M	44	24	100	50	II	II	33	32	+	+	—	+	
(16).....	M	30	16	100	20	II	II	20	15	+	+	—	+	
(17).....	M	21	18	200	43	II	II	4	5	+	+	—	+	Nausea, 22d month; diarrhea, 22d month.
(18).....	M	26	17	100	38	II	II	22	4	+	+	—	+	Nausea, 3d month; headache, 3d month.
(19).....	M	43	22	200	52	II	II	22	12	+	+	—	+	
(20).....	M	32	21	100	40	II	II	10	12	+	+	—	+	
(21).....	M	40	20	150	39	II	II	30	42	+	+	—	+	
(22).....	M	20	14	75	52	II	II	40	44	+	+	—	+	
(23).....	M	47	26	125	21	II	II	37	53	+	+	—	+	
(24).....	M	44	20	100	38	II	II	20	21	+	+	—	+	
(25).....	M	22	18	100	21	II	II	2	82	+	+	—	+	
(26).....	M	55	25	100	6	II	II	102	82	+	+	—	+	
(27).....	F	31	25	50	40	IV	IV	105	105	+	+	—	+	
(28).....	M	53	23	100	6	IV	IV	105	105	+	+	—	+	
(29).....	M	39	36	75	5	II	II	11	11	+	+	—	+	Nausea, 1st month.
Average.....	(⁴)	41	24	100	33	(⁵)	(⁶)	39	26	—	22	17	17	11 months (range 1 to 34 months).
Total.....	(⁴)					(⁵)	(⁶)							13 side effects (8 pts.).

¹ American Rheumatism Association classification: Class I—Ability to carry on a usual duties without handicaps. Class II—Adequate for normal activities despite handicap of discomfort or limited motion of 1 or more joints. Class III—Limited only to little or none of duties of usual occupation or self-care. Class IV—Bedridden or confined to wheelchair; little or no self-care.

² The 4 selected parameters were rated as improved when joint pain decreased in intensity, duration of morning stiffness diminished by at least 1/2 hour, onset of fatigue decreased by at least 2 hours, and the degree of joint mobility increased by 25 percent or more.

³ Overall therapeutic rating scale whereby improvement in 3 or 4 of the selected parameters were graded as good, in 1 or 2 as fair, and in none as poor.

⁴ This woman, with a 15-year history of diabetes, died following a second episode of myocardial infarction. No autopsy was obtained.

⁵ The "p" value obtained from Student's "t" table is statistically significant at the <0.01 level after testing the average paired differences against zero for the ESR values before and after indomethacin.

⁶ Total: Male, 25; female, 3.

⁷ Total by classification: Class I, 1; class II, 21; class III, 5; class IV, 1.

⁸ Total by classification: Class I, 21; class II, 6; class III, 0; class IV, 1.

⁹ Total: Good, 21; fair, 5; poor, 2.